BrainChild Bio Inc

📅 Upcoming

🕒 Recent(90d)

News

• Frazier adds $1.1B+ to small and mid-sized biotech fund
  Frazier’s life science fund has already benefited several successful biotechs, including Verona Pharma, which was acquired by Merck for $10 billion, and Carmot Therapeutics, which Roche bought for…
  biospace · 5d ago
• Encoded raises $275M series F for Dravet syndrome gene therapy
  Encoded Therapeutics’ lead asset ETX101 is a gene therapy being tested for Dravet syndrome. Phase 1/2 data showed substantial reductions in seizures.
  biospace · 6d ago
• BrainChild Bio targets deadly pediatric brain cancer with $116M series A
  BrainChild Bio’s lead asset BCB-276 is in pivotal development for diffuse intrinsic pontine glioma, a rare and fatal brain tumor that affects around 300 children in the U.S. every year.
  biospace · 8d ago
• BrainChild Bio gets $116M for pivotal trial of pediatric brain tumor CAR-T
  A Seattle biotech trying to flip the script on CAR-T cell therapies — making them akin to small molecules for brain tumors — has put together a megaround with the hopes of becoming a commercial-sta…
  endpoints · 8d ago
• BrainChild hauls in $116M to make cell therapies for childhood brain cancers
  Spun out of research at Seattle Children’s Hospital, the startup has brought a CAR-T treatment for a rare and deadly pediatric cancer into mid-stage testing.
  biopharma_dive · 8d ago
• BrainChild Bio masterminds $116M series A for CAR-T's pivotal push in pediatric brain cancer
  A startup spawned from Seattle Children’s Hospital has raised a $116 million series A to advance cell therapies for devastating childhood brain tumors.
  fiercebiotech · 9d ago